Literature DB >> 31742868

Layer-by-layer assembled PLGA nanoparticles carrying miR-34a cargo inhibit the proliferation and cell cycle progression of triple-negative breast cancer cells.

Chintan H Kapadia1, Stephen A Ioele1, Emily S Day1,2,3.   

Abstract

Triple-negative breast cancer (TNBC) accounts for 15-25% of diagnosed breast cancers, and its lack of a clinically defined therapeutic target has caused patients to suffer from earlier relapse and higher mortality rates than patients with other breast cancer subtypes. MicroRNAs (miRNAs) are small non-coding RNAs that regulate the expression of multiple genes through RNA interference to maintain normal tissue function. The tumor suppressor miR-34a is downregulated in TNBC, and its loss-of-expression correlates with worse disease outcomes. Therefore, delivering miR-34a mimics into TNBC cells is a promising strategy to combat disease progression. To achieve this goal, we synthesized layer-by-layer assembled nanoparticles (LbL NPs) comprised of spherical poly(lactic-co-glycolic acid) cores surrounded by alternating layers of poly-L-lysine (PLL) and miR-34a. TNBC cells internalized these LbL NPs to a greater extent than polyplexes comprised of PLL and miRNA, and confocal microscopy showed that LbL NPs delivered a substantial fraction of miR-34a cargo into the cytosol. This yielded robust suppression of the miR-34a target genes CCND-1, Notch-1, Bcl-2, Survivin, and MDR-1, which reduced TNBC cell proliferation and induced cell cycle arrest. These data validate that miR-34a delivery can impair TNBC cell function and support continued investigation of this platform for treatment of TNBC.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  gene regulation; intracellular trafficking; miRNA; nanocarrier; oncology

Year:  2019        PMID: 31742868      PMCID: PMC7103458          DOI: 10.1002/jbm.a.36840

Source DB:  PubMed          Journal:  J Biomed Mater Res A        ISSN: 1549-3296            Impact factor:   4.396


  60 in total

Review 1.  The effect of nanoparticle size, shape, and surface chemistry on biological systems.

Authors:  Alexandre Albanese; Peter S Tang; Warren C W Chan
Journal:  Annu Rev Biomed Eng       Date:  2012-04-18       Impact factor: 9.590

Review 2.  MicroRNA biogenesis: coordinated cropping and dicing.

Authors:  V Narry Kim
Journal:  Nat Rev Mol Cell Biol       Date:  2005-05       Impact factor: 94.444

3.  Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology.

Authors:  Stefan Tenzer; Dominic Docter; Jörg Kuharev; Anna Musyanovych; Verena Fetz; Rouven Hecht; Florian Schlenk; Dagmar Fischer; Klytaimnistra Kiouptsi; Christoph Reinhardt; Katharina Landfester; Hansjörg Schild; Michael Maskos; Shirley K Knauer; Roland H Stauber
Journal:  Nat Nanotechnol       Date:  2013-09-22       Impact factor: 39.213

4.  Distant metastasis in triple-negative breast cancer.

Authors:  L M Tseng; N C Hsu; S C Chen; Y S Lu; C H Lin; D Y Chang; H Li; Y C Lin; H K Chang; T C Chao; F Ouyang; M F Hou
Journal:  Neoplasma       Date:  2013       Impact factor: 2.575

5.  Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer.

Authors:  Christopher L Daige; Jason F Wiggins; Leslie Priddy; Terri Nelligan-Davis; Jane Zhao; David Brown
Journal:  Mol Cancer Ther       Date:  2014-07-22       Impact factor: 6.261

Review 6.  Nanoparticle-blood interactions: the implications on solid tumour targeting.

Authors:  James Lazarovits; Yih Yang Chen; Edward A Sykes; Warren C W Chan
Journal:  Chem Commun (Camb)       Date:  2015-02-18       Impact factor: 6.222

7.  MicroRNA: Biogenesis, Function and Role in Cancer.

Authors:  Leigh-Ann Macfarlane; Paul R Murphy
Journal:  Curr Genomics       Date:  2010-11       Impact factor: 2.236

8.  MicroRNA therapeutics: principles, expectations, and challenges.

Authors:  Rajesha Rupaimoole; Hee-Dong Han; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Chin J Cancer       Date:  2011-06

Review 9.  The fate of chemoresistance in triple negative breast cancer (TNBC).

Authors:  Elma A O'Reilly; Luke Gubbins; Shiva Sharma; Riona Tully; Matthew Ho Zhing Guang; Karolina Weiner-Gorzel; John McCaffrey; Michele Harrison; Fiona Furlong; Malcolm Kell; Amanda McCann
Journal:  BBA Clin       Date:  2015-03-12

Review 10.  microRNA-34a as a Therapeutic Agent against Human Cancer.

Authors:  Yoshimasa Saito; Toshiaki Nakaoka; Hidetsugu Saito
Journal:  J Clin Med       Date:  2015-11-16       Impact factor: 4.241

View more
  12 in total

Review 1.  Non-viral vectors for RNA delivery.

Authors:  Yi Yan; Xiao-Yu Liu; An Lu; Xiang-Yu Wang; Lin-Xia Jiang; Jian-Cheng Wang
Journal:  J Control Release       Date:  2022-01-10       Impact factor: 9.776

Review 2.  Host miRNA and immune cell interactions: relevance in nano-therapeutics for human health.

Authors:  Yogesh Sharma; Adesh K Saini; Sheetal Kashyap; Gourav Chandan; Narinder Kaur; Vijai Kumar Gupta; Vijay Kumar Thakur; Vipin Saini; Reena V Saini
Journal:  Immunol Res       Date:  2021-10-29       Impact factor: 2.829

3.  Critical Evaluation of Different Lysosomal Labeling Methods Used to Analyze RNA Nanocarrier Trafficking in Cells.

Authors:  Shoaib Iqbal; Benjamin Luo; Jilian R Melamed; Emily S Day
Journal:  Bioconjug Chem       Date:  2021-09-20       Impact factor: 6.069

Review 4.  Biomaterials for Hemostasis.

Authors:  Aryssa Simpson; Anita Shukla; Ashley C Brown
Journal:  Annu Rev Biomed Eng       Date:  2022-03-01       Impact factor: 11.324

Review 5.  Strategies to deliver RNA by nanoparticles for therapeutic potential.

Authors:  Alysia Cox; Siyoung A Lim; Eun Ji Chung
Journal:  Mol Aspects Med       Date:  2021-08-05

6.  Photoresponsive miR-34a/Nanoshell Conjugates Enable Light-Triggered Gene Regulation to Impair the Function of Triple-Negative Breast Cancer Cells.

Authors:  Megan N Dang; Carolina Gomez Casas; Emily S Day
Journal:  Nano Lett       Date:  2020-12-11       Impact factor: 11.189

7.  Down-regulation of the tumor suppressor miR-34a contributes to head and neck cancer by up-regulating the MET oncogene and modulating tumor immune evasion.

Authors:  Xun Wu; Yi-Shing Lisa Cheng; Mathew Matthen; Angela Yoon; Gary K Schwartz; Shashi Bala; Alison M Taylor; Fatemeh Momen-Heravi
Journal:  J Exp Clin Cancer Res       Date:  2021-02-17

Review 8.  Recent Advances in the Development of Exogenous dsRNA for the Induction of RNA Interference in Cancer Therapy.

Authors:  Tatiana S Golubeva; Viktoria A Cherenko; Konstantin E Orishchenko
Journal:  Molecules       Date:  2021-01-29       Impact factor: 4.411

9.  miR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer.

Authors:  Silvia Martini; Valentina Zuco; Monica Tortoreto; Stefano Percio; Elisa Campi; Rihan El Bezawy; Valentina Doldi; Yosef Landesman; Marzia Pennati; Nadia Zaffaroni
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-29

10.  Dual Regulation of miR-34a and Notch Signaling in Triple-Negative Breast Cancer by Antibody/miRNA Nanocarriers.

Authors:  Danielle M Valcourt; Emily S Day
Journal:  Mol Ther Nucleic Acids       Date:  2020-06-09       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.